The Korean Journal of Cytopathology (대한세포병리학회지)

The Korean Society for Cytopathology (대한세포병리학회)
권호 표지
DOI QR코드

DOI QR Code

Methylation Abnormality in Body Fluid Cytology: A Supplemental Molecular Marker for the Diagnosis of Malignant Mesothelioma

체액 세포 도말 검사에서 메틸화 이상이 악성 중피종 진단의 부가적인 분자 표지자로서의 기능

  • Song, Joon-Seon (Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Jung, Jin-Kyung (Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Kang, Ji-Hye (Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Hwang, Il-Seon (Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Jang, Se-Jin (Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center)
  • 송준선 (울산대학교의과대학 서울 아산병원 병리과) ;
  • 정진경 (울산대학교의과대학 서울 아산병원 병리과) ;
  • 강지혜 (울산대학교의과대학 서울 아산병원 병리과) ;
  • 황일선 (울산대학교의과대학 서울 아산병원 병리과) ;
  • 장세진 (울산대학교의과대학 서울 아산병원 병리과)
  • Published : 2008.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Malignant mesothelioma (MM) is a highly lethal neoplasm arising in pleura and the peritoneum and a rapid and accurate diagnosis is crucial for treatment of the disease. However, the sensitivity of cytological analysis using pleural or ascitic fluid is relatively low, yielding an accurate diagnosis in only $32{\sim}79%$ of cases. We tested the diagnostic value of epigenetic alterations in body fluid cytology as a supplement to conventional methods. Paraffin-embedded tissue blocks from 21 MM patients and associated body fluid cytology slides considered no evidence of malignancy were used to test for epigenetic alteration. Using methylation-specific PCR, we detected methylation of RASSF1A and p16 in 47.6% (10/21) of both surgically resected tumor samples, respectively. Body fluid samples of MM also showed abnormal methylation of RASSF1A and p16INK4a genes in 38.1% (8/21) and 33.3% (7/21) of cases. The concordance in the rates of RASSF1A and p16INK4a gene-methylation abnormalities determined from cytology samples and tissue samples were 61.9% (13/21) and 66.7% (14/21), respectively. Combining both genes increases the sensitivity of the test to 57.1 % (12 of 21) of cases. Our results suggest that testing for methylation abnormalities in selected individual genes or gene combinations has diagnostic value as an alternative or adjunct method to conventional cytological diagnosis.

Keywords

References

  1. Antman KH, Schiff PB and Pass HI Cancer: Principles and Practice of Oncology. 5th edition ed. Philadelphia: Lippincott, 1997; 1853-78
  2. DiBonito L, Falconieri G, Colautti I, Bonifacio Gori D, Dudine S, Giarelli L. Cytopathology of malignant mesothelioma: a study of its patterns and histological bases. Diagn Cytopathol 1993;9:25-31 https://doi.org/10.1002/dc.2840090106
  3. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 1997;111:106-9 https://doi.org/10.1378/chest.111.1.106
  4. Teirstein AS. Diagnosing malignant pleural mesothelioma. Chest 1998;114:666-7 https://doi.org/10.1378/chest.114.3.666
  5. Whitaker D, Shilkin KB. Mesotheliomas. Gray W 2nd ed. New York: Churchill Livingstone, 1995; 195-224
  6. Whitaker D, Shilkin KB. Early diagnosis of malignant mesothelioma: the contribution of effusion and fine needle aspiration cytology and ancillary techniques. New York: Garland Law Publishing, 1989; 71-115
  7. Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002;21:5450-61 https://doi.org/10.1038/sj.onc.1205605
  8. Marsit CJ, Houseman EA, Christensen BC, et al. Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res 2006;66:10621-9 https://doi.org/10.1158/0008-5472.CAN-06-1687
  9. Jair KW, Bachman KE, Suzuki H, et al. De novo CpG island methylation in human cancer cells. Cancer Res 2006;66:682-92 https://doi.org/10.1158/0008-5472.CAN-05-1980
  10. Fujiwara K, Fujimoto N, Tabata M, et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 2005;11:1219-25
  11. Wang J, Lee JJ, Wang L, et al. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res 2004;10:6119-25 https://doi.org/10.1158/1078-0432.CCR-04-0652
  12. Toyooka S, Suzuki M, Maruyama R, et al. The relationship between aberrant methylation and survival in non-smallcell lung cancers. Br J Cancer 2004;91:771-4 https://doi.org/10.1038/sj.bjc.6602013
  13. Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 2002;23:1127-30 https://doi.org/10.1093/carcin/23.7.1127
  14. Wong L, Zhou J, Anderson D, Kratzke RA. Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 2002;38:131-6 https://doi.org/10.1016/S0169-5002(02)00178-2
  15. Toyooka S, Carbone M, Toyooka KO, et al. Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells. Oncogene 2002;21:4340-4 https://doi.org/10.1038/sj.onc.1205381
  16. Toyooka S, Pass HI, Shivapurkar N, et al. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res 2001;61:5727-30
  17. Chan EC, Lam SY, Tsang KW, et al. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage. Clin Cancer Res 2002;8:3741-6
  18. Toyooka S, Toyooka KO, Maruyama R, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001;1:61-7
  19. Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y, Motoyama T. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 2003;94:589-92 https://doi.org/10.1111/j.1349-7006.2003.tb01487.x
  20. Harden SV, Tokumaru Y, Westra WH, et al. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 2003;9:1370-5
  21. Zhou JX, Niehans GA, Shar A, Rubins JB, Frizelle SP, Kratzke RA. Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer. Lung Cancer 2001;32:27-38 https://doi.org/10.1016/S0169-5002(00)00210-5
  22. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6 https://doi.org/10.1073/pnas.93.18.9821
  23. Fackler MJ, McVeigh M, Evron E, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003;107:970-5 https://doi.org/10.1002/ijc.11508
  24. Pu RT, Laitala LE, Alli PM, Fackler MJ, Sukumar S, Clark DP. Methylation profiling of benign and malignant breast lesions and its application to cytopathology. Mod Pathol 2003;16:1095-101 https://doi.org/10.1097/01.MP.0000095782.79895.E2
  25. Pu RT, Sheng ZM, Michael CW, Rhode MG, Clark DP, O'Leary TJ. Methylation profiling of mesothelioma using real-time methylation-specific PCR: a pilot study. Diagn Cytopathol 2007;35:498-502 https://doi.org/10.1002/dc.20692
  26. Kobayashi N, Toyooka S, Yanai H, et al. Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer 2008 [EPub ahead of print]
  27. Kim H, Kwon YM, Kim JS, et al. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol 2004;22:2363-70 https://doi.org/10.1200/JCO.2004.10.077
  28. Topaloglu O, Hoque MO, Tokumaru Y, et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 2004;10:2284-8 https://doi.org/10.1158/1078-0432.CCR-1111-3
  29. Benlloch S, Galbis-Caravajal JM, Martin C, et al. Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion. Cancer 2006;107:1859-65 https://doi.org/10.1002/cncr.22190
  30. Fischer JR, Ohnmacht U, Rieger N, et al. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 2006;54:109-16 https://doi.org/10.1016/j.lungcan.2006.06.017
  31. Ramirez JL, Rosell R, Taron M, et al. 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatinplus- gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin Oncol 2005;23:9105-12 https://doi.org/10.1200/JCO.2005.02.2905
  32. Ramirez JL, Sarries C, de Castro PL, et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett 2003;193:207-16 https://doi.org/10.1016/S0304-3835(02)00740-1
  33. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70

Cited by

  1. Utility of Promoter Hypermethylation for Differentiating Malignant and Benign Effusions in Liquid-Based Cytology Specimens vol.44, pp.3, 2010, https://doi.org/10.4132/koreanjpathol.2010.44.3.315